Skip to content
InsideEdge
Investors / filer profile

No completed buy history yet — outcomes appear once a disclosed buy is ~6 months old.

Disclosed positions

Estimated from their latest filings — positions may have changed since

Activity

Open-market buy & sell volume

BuySell
0$2.0M$3.9M2025 · bought $0 · sold $3.9M20252026 · bought $0 · sold $526K2026
Total +$0.0000 bought · $4.45M sold

All filings on record

Every Form 4 transaction we track for this filer

RNAMReturn
2026-02-27 · Avidity Biosciences, Inc.
115,857
RNASell
2026-01-21 · Atrium Therapeutics, Inc.
$208.5K
RNASell
2026-01-21 · Atrium Therapeutics, Inc.
$146.1K
RNASell
2026-01-07 · Atrium Therapeutics, Inc.
$171.4K
RNASell
2025-10-22 · Atrium Therapeutics, Inc.
$105.0K
RNAExercise
2025-10-22 · Atrium Therapeutics, Inc.
$22.4K
RNASell
2025-09-22 · Atrium Therapeutics, Inc.
$89.6K
RNAExercise
2025-09-22 · Atrium Therapeutics, Inc.
$22.4K
RNASell
2025-09-15 · Atrium Therapeutics, Inc.
$70.0K
RNAExercise
2025-09-15 · Atrium Therapeutics, Inc.
$10.1K
RNASell
2025-08-22 · Atrium Therapeutics, Inc.
$102.5K
RNAExercise
2025-08-22 · Atrium Therapeutics, Inc.
$22.4K
RNASell
2025-08-13 · Atrium Therapeutics, Inc.
$71.9K
RNAExercise
2025-08-13 · Atrium Therapeutics, Inc.
$10.1K
RNASell
2025-08-06 · Atrium Therapeutics, Inc.
$1.45M
RNASell
2025-08-06 · Atrium Therapeutics, Inc.
$755.0K
RNAExercise
2025-08-06 · Atrium Therapeutics, Inc.
$179.5K
RNASell
2025-08-06 · Atrium Therapeutics, Inc.
$263.6K
RNAExercise
2025-08-06 · Atrium Therapeutics, Inc.
$138.6K
RNASell
2025-08-06 · Atrium Therapeutics, Inc.
$527.1K
RNAExercise
2025-08-06 · Atrium Therapeutics, Inc.
$81.0K
RNASell
2025-08-06 · Atrium Therapeutics, Inc.
$482.2K
RNAExercise
2025-08-06 · Atrium Therapeutics, Inc.
$180.1K

Outcomes measure each disclosed buy against the closing price ~6 months (120 trading days) later, with the S&P 500 over the same span for context. Pre-scheduled 10b5-1 plan trades are excluded from the record. Positions are estimated from the latest reported post-transaction holdings, split-adjusted, at the latest close. Built from SEC Form 4 filings and market prices — past outcomes, not predictions or advice.